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Abstract
The rate of blastformation of peripheral blood lymphocytes in response to stimulation by phy-
tohemagglutinin (PHA) was assessed preoperatively in 393 patients with gastrointestinal cancer.
The series consisted of 291 cases of gastric cancer and 102 cases of colon cancer, all patients be-
ing under 70 years of age. The blastformation rate was related to the stage of cancer ground at
operation. Preoperative blastformation rates for both colon cancer and gastric cancer decreased as
the cancer progressed. With Stage I gastric cancer 81.4% of those that underwent curative resec-
tion had preoperative blastformation rates greater than 40%. However, the number of those with
blastformation rates over 40% decreased markedly in the curative cases of gastric cancer Stage
II to stage IV. Eighty three percent of cases that underwent curative resection with colon cancer,
including advanced cancer, had preoperative blastformation rates of over 40%. These results indi-
cated that the correlation of the preoperative blastformation rate with success of curative resection
better for colon cancer than for gastric cancer.
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Abstract. The rate of blastformation of peripheral blood lympho-
cytes in response to stimulation by phytohemagglutinin (PHA) was
assessed preoperatively in 393 patients with gastrointestinal cancer.
The series consisted of 291 cases of gastric cancer and 102 cases of
colon cancer, all patients being under 70 years of age. The blastfor-
mation rate was related to the stage of cancer ground at operation.
Preoperative blastformation rates for both colon cancer and gastric
cancer decreased as the cancer progressed. With Stage I gastric can-
cer, 81.4% of those that underwent curative resection had preoperative
blastformation rates greater than 40%. However, the number of
those with blastformation rates over 40% decreased markedly in the
curative cases of gastric cancer Stage II to stage IV. Eighty three
percent of cases that underwent curative resection with colon cancer,
including advanced cancer, had preoperative blastformation rates of
over 40%. These results indicated that the correlation of the pre-
operative blastformation rate with success of curative resection better
for colon cancer than for gastric cancer.
Many attempts have been made to analyse cancer patients clinically at an
immunological level. It is now possible to predict the progress of cancer from
the cell-mediated immunity of the cancer-bearing host (1-3). For the past ten
years, we have been studing cell-mediated immunity in callcer-bearing patients,
concentrating on the use of nonspecific immune reactions as a parameter for
assessing the development of cancer and the possibility of curative resection.
So far, the blastformation rate of peripheral blood lymphocytes against PHA
(as abbreviated to the blastformation rate) has proved the most effective non-
specific immune reaction in the case of gastric cancer (4, 5). The present paper
is an extension of this study to include cases of colon cancer as well as many cases
of gastric cancer. It does, therefore, provide a general picture of gastrointestinal
cancer and comfirms the usefulness of the preoperative blastformation rate in
determining surgical treatment for gastrointestinal cancer patients.
MATERIALS AND METHODS
Subjects. The rate of blastformation of peripheral blood lymphocytes was
assessed preoperatively in 393 patients with gastrointestinal cancer who had
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been admitted to our surgical department. The series consisted of 291 cases of
gastric cancer and 102 cases of colon cancer, all patients beeing under 70 years
of age, and was divided into three groups after operation: curative resection,
noncurative resection, and nonresectable. Recurrent cases (6), and those of
over 70 years old (7) whose cell-mediated immunity was markedly low were
excluded from the series.
Methods. Fairly pure, small lymphocytes were isolated from a 5 ml pre-
operative specimen of heparinized peripheral blood by the Ficoll-Conray me-
thod. These lymphocytes were suspended in 2ml of TC-199 solution containing
20% calf serum at a concentration of 106 cells Iml, then 1% (vIv) PHA-M (Difco)
added. The lymphocytes were cultured in TD-15 for 72 hr, centrifuged, and
the sediment smeared on a slide glass and stained with May-Giemsa stain. The
number of lymphocytes over (8,um)2 in size in 103 lymphocytes was used to
estimate the blastformation rate as in the following formula (4-6) :
number of lymphocytes over (8!~m)2 in size X 100blastformation rate (%) TOfTy~phocytes
RESULTS
In gastrointestinal cancer patients under 70 years of age who received cura-
tive resection, the mean ± SD for the blastformation rate was 5a± 15 % and the
incidence of those having blastformation rates over 40 % was more than 70 %.
In similar patients over 70 years of age, the blastformation rate was 38.5 ± 16.9%
and 43.8% of them were over 40%. The blastformation rate was sometimes
low in cases over 70 years old. It was not considered appropriate, therefore,
to analyse blastformation rates without respect to age, so all of following results
are for those under 70 years of age.
The preoperative blastformation rate in gastrointestinal cancer patients was,
as already reported previously (4), markedly low about 1/2 that of normal indi-
viduals or patients with diseases other than cancer.
The relationship between the preoperative blastformation rate and the stage
classification at the time of operation in 291 cases of gastric cancer was as fol-
lows: the blastformation rate at Stages I, II, III, and IV was 51.1 ± 15.5, 45.9±
17.3, 41.3± 15.0 and 27.8± 14.4% respectively, indicating that the blastforma-
tion rate decreased as gastric cancer advanced (Fig. 1). The blastformation rate
in 80 cases of Stage I and II, all of whom received curative resection, was 49.3 ±
16.9 %, while 38 of 57 cases of Stage III and 9 of 84 cases of Stage IV all of whom
underwent curative resection had preoperative blastformation rates of 46.6 ±
16.5 %. When the cases of Stage IV were divided resectable and non-resectable
groups, the blastformation rate was 3fi.5± 16.3% in the former and 27.8± 1404%
in the latter. Cases of gastric cancer undergoing curative resection with preopera-
tive blastformation rates over 40 % decreased in number with cancer advance.
An unexpected finding was that, in the cases Stage II gastric cancer in which
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curative resection had been almost always possible, number with a blastformation
rate of greater than 40 % was ext~emely low (Table I).
With colon cancer, the preoperative blastformation rate in 47 cases of cura-
tive resection was 48.6 ± 14.3 %, 35.7 ± 13.3 % in 23 cases of noncurative resec-
tion, and 25.4 ± 11.4 % in 32 cases of the nonresectable group. These results
show a more clear-cut trend than that seen in the gastric cancer patients (Fig. 2).
In cases of colon cancer (including advanced cases) which underwent curative
resection, the numbers with preoperative blastformation rates over 40% were
higher than in gastric cancer cases· (Table 1).
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Fig. 1. Advance of gastric cancer and b1astformation rate. Numbers of cases
of the stage I, II, III, IVa and IVb are 43,37,57,84 and 70, respectively. Data indi-
cate mean± S.D. IVa, resectable; IVb, nonresectable.
TABLE 1. FREQUENCY OF CASES WITH THE BLASTFORMA TION RATE OF OVER 40%
IN THOSE UNDERGOING CURATIVE RESECTION OF GASTROINTESTINAL CANCER
Diseases
Gastric cancer
(Stage)
Colon cancer
No. of %cases
I 35/43 81.4\II 25/37 67.6 70.9
III 25/38 65.8 74. 1
IV 5/9 55.6
39/47 83.0
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Fig. 2. Advance of colon cancer and blastformation rate. Numbers of cases are
47 for curative resection, 23 for noncurative resection and 32 for nonresectable cases.
Data indicate mean ± S.D.
The overall results for preoperative blastformation rates in this series of
gastrointestinal cancers were: curative resection, 47.2 ± 15. 7% and nonresect-
able operation, 27.1 ± 13.5%.
DISCUSSION
An immunological approach to the clinical assessment of cancer is being
developed and, at present, is based on cell-mediated immunity. Specific immune
tests for estimating this cell-mediated immunity include macrophage migration
inhibition test (8) and the mixed lymphocyte tumor cell reaction. Nonspecific
tests include in vitro estimation of the blastformation rate of peripheral blood
lymphocytes against PHA, pockweed mitogen, or concanavalin A, the incidence
of T-cells and B-cellls (9), and carcinoembryonic antigen. In vivo tests include
skin tests to mumps antigen and tetanus toxoid as well as DNCB and PPD (1-3).
The specific immune tests are based on the response of lymphocytes of the
cancer-bearing patient to antigenic material from cancer of the same patient and
are a good indication of the clinical condition of that cancer patient. Since the
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antigenic material used is cancer tissue, however, it is not possible to assess the
cancer progress by this test prior to operation.
The nonspecific immune tests reflect the response only from the ,cancer-
bearing patient and dose not need cancer tissue. It has been ~eported, however,
that the nonspecific immune tests using DNCB and PPD indicated fairly accu-
rately the cancer progress and prognosis in lung and breast cancer patients (1, 10).
There are, as yet, few reports of the use of immune tests with gastrointestinal
cancer (3, 5, 11).
In our previous report (5), we examined 188 cases of surgery for gastric
cancer, and found that when gastric cancer progresssed, the blastformation rate
decreased. We postulated that the preoperative blastformation rate might reflect
the extent of gastric cancer such that, if the preoperative blastformation rate was
over 40%, curative resection might be considered, whereas if it was less than
30 %, palliative surgery should be the treament.
In the present paper, we report that not only in gastric cancer, but also in
colon cancer and in gastrointestinal cancer as a whole, the preoperative blast-
formation rate enabled us to determine before operation whether or not curative
resection was possible. That is if the preoperative blastformation rate is over
40 %, curative resection might be considered, whereas if it is less than 40 % non-
curative resection or nonresection should be the treament in gastrointestinal
cancer.
The blastformation rate is also useful for assessing the prognosis of gastroin-
testinal cancer patients. We previously reported that the blastformation rate in
gastrointestinal cancer patients suddenly fell 2 months before recurrence after
curative resection. So the blastformation rate should be a significant improve-
ment in predicting recurrence of cancer if routinely monitered postoperatively
(6). When the clinical course is good and cancer recurrence is avoided, the blast-
formation rate is maintained at over 40% in gastrointestinal cancer patients after
curative resection. We intend to report in detail on this point in the near future.
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